FDA Approves Gilead's Antiretroviral Viread for Use as Hepatitis B Treatment
August 13, 2008
Gilead Sciences on Monday announced that it has received FDA approval to market its antiretroviral drug Viread as a hepatitis B treatment, the AP/International Herald Tribune reports (AP/International Herald Tribune, 8/12). According to Gilead estimates, more than 400 million people worldwide have hepatitis B, an infection that affects the liver and is prevalent in Asia. The disease is the leading cause of liver cancer, and complications associated with hepatitis B result in up to 1.2 million deaths annually.
Expanded Indication for Viread, to Include the Treatment of Patients 12 to Less Than 18 Years of Age
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.